Retension Pharmaceuticals raised $10.4 million in a Series A funding led by undisclosed investors to fund clinical trials for patients suffering from resistant and uncontrolled hypertension.
Amount Raised
$10.4 Million
Round Type
Series A
McleanBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Retension Pharmaceuticals announced the successful closing of its $10.4 million Series A financing round to initiate a Phase 2 clinical study for patients with uncontrolled hypertension. The company is focused on developing innovative treatments for hypertension and cardiovascular disease.
Quick answer
Retension Pharmaceuticals raised $10.4 Million in a Series A round, dated August 21, 2024. Retension Pharmaceuticals is based in Mclean, Virginia, United States.
- How much did Retension Pharmaceuticals raise?
- Retension Pharmaceuticals raised $10.4 Million in a Series A round on August 21, 2024.
- What does Retension Pharmaceuticals do?
- Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension.
- Where is Retension Pharmaceuticals based and how big is it?
- Retension Pharmaceuticals is based in Mclean, Virginia, United States. Fundz records about 10 employees.
- Who are the decision-makers at Retension Pharmaceuticals?
- Fundz holds 1 contact at Retension Pharmaceuticals. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Therapeutics around the same time
Companies in the same sectors as Retension Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.
- Lipella Pharmaceuticals raised $120K on July 31, 2024.
- OnKure Therapeutics raised $65M on October 4, 2024.
- Cumulus Oncology raised $50M (Series A) on September 3, 2024.
- Pathalys Pharma raised $105M (Series B) on August 21, 2024.
- Pelthos Therapeutics raised $750K on July 24, 2024.
- Ensho Therapeutics raised $400K on July 19, 2024.
Who to call at Retension Pharmaceuticals, and when
A new round usually means Retension Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Retension Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Retension Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Retension Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Retension Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansRetension Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.